ArticleCancer research and treatment2026
Pancreatic Irradiation Dose as a Risk Factor for Elevation in Hemoglobin A1c Level and Diabetes Mellitus in Patients with Indolent Gastroduodenal Lymphoma.
Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study investigated the association between pancreatic irradiation dose and hemoglobin A1c (HbA1c) elevation in patients with indolent gastroduodenal lymphomas treated with radiotherapy (RT). MATERIALS AND
methodsWe retrospectively reviewed 103 patients treated at Samsung Medical Center between 2010 and 2023, with or without RT. Patients were stratified by mean pancreas dose (< 2,300 cGy vs. ≥ 2,300 cGy). The primary outcome was the 2-year HbA1c elevation, with additional time-to-event analyses for HbA1c elevation ≥ 0.5% and diabetes mellitus (DM) development.
resultsRT was administered to 62 (60.2%) patients, while 41 (39.8%) did not receive RT. There was no significant difference in baseline characteristics except for cancer type. Patients with a mean pancreas dose ≥ 2,300 cGy had a significantly greater 2-year HbA1c increase than those receiving < 2,300 cGy (p=0.003) or no RT (p < 0.001). No significant difference was found between patients receiving < 2,300 cGy and those without RT (p=0.120). In multivariate time-to-event analysis, a mean pancreas dose ≥ 2,300 cGy was the sole significant risk factor for an HbA1c increase ≥ 0.5% (p < 0.001), while mean pancreas dose < 2,300 cGy did not show a significant effect (p=0.851). Furthermore, a mean pancreas dose ≥ 2,300 cGy (p=0.017) and baseline prediabetes (HbA1c ≥ 5.7%) (p=0.023) were independent predictors of DM development.
conclusionA mean pancreas dose ≥ 2,300 cGy was associated with HbA1c elevation, whereas doses < 2,300 cGy had minimal effect. Given the established link between higher HbA1c level and increased risk of DM and cardiovascular events, pancreatic dose reduction should be considered in RT planning for patients with an expected good prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.